Molecular diagnostics company Veracyte raises $28m C funding with GE Ventures as a new investor.
Veracyte, a US-based molecular diagnostics company in the field of molecular cytology, has completed the final tranche of its $28m series C financing which includes GE Ventures (the corporate venturing unit of industrial conglomerate General Electric) as a new investor. All previous investors participated in the round, including venture capital and private equity investors Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, and Versant Ventures.
Bonnie Anderson, Veracyte’s co-founder and chief executive officer., said: “We are pleased to have…
